Episode 2: Overcoming Barriers in HAE Treatment

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI

Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI

This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.

Learning Objective:

After listening to this podcast episode, participants should be better able to:

• Create effective treatment plans for their specific population (minority, rural, urban)

References:

1. Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.


2. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.


3. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3


4. Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022

Speaker Disclosures:

Kristin C. Sokol, MD, MS, MPH, FACAAI

Advisor: Sanofi, Genentech, SELF/Conde Nast

Jonathan A. Bernstein, MD, FACAAI

Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva

Timothy J. Craig, DO, FACAAI

Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda

Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda

Independent Contractor: Kalvista, Phavaris

Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda

Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda

This podcast miniseries is supported by a grant from Takeda.